Intensive intravesical mitomycin C therapy in non-muscle-invasive bladder cancer: A dose intensity approach

Urologia Internationalis

Volumn 85, Issue 3, 2010, Pages 266-269

  Racioppi, Marco ^a,b   Volpe, Andrea ^a   Cappa, Emanuele ^a   D'Agostino, Daniele ^a   Pinto, Francesco ^a   D'Addessi, Alessandro ^a   Sacco, Emilio ^a   Bassi, Pierfrancesco ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

Mitomycin C; Non muscle invasive bladder cancer; Transurethral resection

Indexed keywords

MITOMYCIN C;

ADULT; AGED; ARTICLE; BLADDER CANCER; BLOOD CELL COUNT; CANCER PATIENT; CANCER SURGERY; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTITIS; CYSTOSCOPY; DRUG TOLERABILITY; ERYTHEMA; FEMALE; FOLLOW UP; HEMATURIA; HUMAN; MALE; NON MUSCLE INVASIVE BLADDER CANCER; PRIORITY JOURNAL; TRANSURETHRAL RESECTION;

ADMINISTRATION, INTRAVESICAL; AGED; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MITOMYCIN; NEOPLASM INVASIVENESS; TIME FACTORS; TREATMENT OUTCOME; URETHRA; URINARY BLADDER NEOPLASMS;

EID: 78049476171     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000315492     Document Type: Article

References (20)

1. Pawinski A, Sylverster R, Kurth KH, et al: A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage Ta T1 bladder cancer. J Urol 1996; 156: 1934-1941. (Pubitemid 26378022)
2. Lamm DL, Blumenstein BA, Crissman JD, et al: Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: A randomized Southwest Oncology Group Study. J Urol 2000; 163: 1124-1129.
3. Fuji Y, Kwakami S, Koga F, et al: Long-term outcomes of bladder papillary urothelial neoplasms of malignant potential. BJU Int 2003; 92: 559-562. (Pubitemid 37271729)
4. Kamat AH, Lamm DL: Intravesical therapy for bladder cancer. Urology 2000; 55: 161-168.
5. Witjes JA, Mungan NA, Debruyne NJ: Management of superficial bladder cancer with intravesical chemotherapy: An update. Urology 2000; 56: 19-21. (Pubitemid 30408645)
6. Spataro V, Bonadonna G: Principi di distruzione e resistenza cellulare; in Bonadonna G, Robustelli Della Cuna G, Valagussa P (eds): Medicina Oncologica, ed 8. Milan, Elsevier Masson, 2003, chap 22, pp 459-479.
7. Bolenz C, Cao Y, Arancibia MF, et al: Intravesical mitomycin C for superficial transitional cell carcinoma. Expert Rev Anticancer Ther 2006; 6: 1273-1282. (Pubitemid 44304695)
8. Kurth K, Tunn U, Ay R, et al: Adjuvant chemotherapy for superficial transitional cell carcinoma: Long-term results of a European Organisation for Research and Treatment of Cancer. Randomized trial comparing doxorubicin, ethoglucid and transurethral resection alone. J Urol 1997; 158: 378-384. (Pubitemid 27327671)
9. Malmström PU, Wijstrom H, Lundholm C, et al: 5-year follow-up of a randomized prospective study comparing mitomycin C and BCG in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group. J Urol 1999; 161: 1124-1127. (Pubitemid 29426100)
10. Krege S, Giani G, Meyer R, et al: A randomized multicentric trial of adjuvant therapy in superficial bladder cancer: Transurethral resection only versus transurethral resection plus mitomicyn C versus transurethral resection plus bacillus Calmette-Guerin. Participating clinics. J Urol 1996; 156: 962-966. (Pubitemid 26269810)
11. Au JL, Badalament RA, Wientjes MG, et al: Methods to improve efficacy of mitomycin C: Results of a randomized phase III trial. J Natl Cancer Inst 2001; 93: 597-604. (Pubitemid 32409627)
12. Tolley DA, Parmar MK, Grigor KM, et al: The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: A further report with 7 years of follow-up. J Urol 1996; 155: 1233-1238.
13. Malmström PU: Intravesical therapy of superficial bladder cancer. Crit Rev Oncol Hematol 2003; 47: 109-126. (Pubitemid 36957860)
14. Badalament RA, Farah RN: Treatment of superficial bladder cancer with intravesical chemotherapy. Semin Surg Oncol 1997; 13: 335-341. (Pubitemid 27332856)
15. De Bruijn EA, Sleeboom HP, van Helsdingen PJ, et al: Pharmacodynamics and pharmacokinetics of intravesical mitomycin C upon different dwelling times. Int J Cancer 1992; 51: 359-364.
16. Schmidbauer CP, Porpaczy P, Georgeopoulos A, et al: Absorption of doxorubicin-hydrochloride and mitomycin C after instillation into non infected and infected bladders of dog. J Urol 1984; 131: 818-821. (Pubitemid 14109653)
17. Dalton JT, Wientjes MG, Badalament RA, et al: Pharmacokinetics of intravesical mitomycin C in superficial bladder cancer patients. Cancer Res 1991; 51: 5144-5152.
18. Racioppi M, Porreca A, Foschi N, et al: Bladder perforation: A potential risk of early endovesical chemotherapy with mitomycin C. Urol Int 2005; 75: 373-375. (Pubitemid 41752592)
19. Gårdmark T, Jahnson S, Wahlquist R, et al: Analysis of progression and survival after 10 years of a randomized prospective study comparing mitomycin-C and bacillus Calmette-Guérin in patients with highrisk bladder cancer. BJU Int 2007; 99: 817-820. (Pubitemid 46439578)
20. Sylvester RJ, van der Meijden APM, Witjes JA, et al: Bacillus Calmette-Guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: A meta-analysis of the published results of randomized clinical trial. J Urol 2005; 174: 86-92.